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Abstract
Although the substantial burdens of rotavirus and pneumococcal disease have motivated many countries to consider
introducing the rotavirus vaccine (RV) and heptavalent pneumococcal conjugate vaccine (PCV-7) to their National
Immunization Programs (EPIs), these new vaccines could affect the countries’ vaccine supply chains (i.e., the series of steps
required to get a vaccine from their manufacturers to patients). We developed detailed computational models of the Trang
Province, Thailand, vaccine supply chain to simulate introducing various RV and PCV-7 vaccine presentations and their
combinations. Our results showed that the volumes of these new vaccines in addition to current routine vaccines could
meet and even exceed (1) the refrigerator space at the provincial district and sub-district levels and (2) the transport cold
space at district and sub-district levels preventing other vaccines from being available to patients who arrive to be
immunized. Besides the smallest RV presentation (17.1 cm
3/dose), all other vaccine introduction scenarios required added
storage capacity at the provincial level (range: 20 L–1151 L per month) for the three largest formulations, and district level
(range: 1 L–124 L per month) across all introduction scenarios. Similarly, with the exception of the two smallest RV
presentation (17.1 cm
3/dose), added transport capacity was required at both district and sub-district levels. Added transport
capacity required across introduction scenarios from the provincial to district levels ranged from 1 L–187 L, and district to
sub-district levels ranged from 1 L–13 L per shipment. Finally, only the smallest RV vaccine presentation (17.1 cm
3/dose)
had no appreciable effect on vaccine availability at sub-districts. All other RV and PCV-7 vaccines were too large for the
current supply chain to handle without modifications such as increasing storage or transport capacity. Introducing these
new vaccines to Thailand could have dynamic effects on the availability of all vaccines that may not be initially apparent to
decision-makers.
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Introduction
Although the substantial burdens of rotavirus and pneumococ-
cal disease have motivated many countries to consider introducing
the rotavirus vaccine (RV) and heptavalent pneumococcal
conjugate vaccine (PCV-7) to their National Immunization
Programs (EPIs), these new vaccines could affect the countries’
vaccine supply chains (i.e., the series of steps required to get a
vaccine from the manufacturers to the arms and mouths of
patients). Vaccine vials can come in different presentations, i.e.,
the physical appearance and composition of the vaccine vial and
associated packaging. For example, a vial can contain different
numbers of vaccine doses (e.g., a single dose, 2-doses, 10-doses, or
20-doses). Moreover, vaccines can be in liquid or powder form, the
latter requiring reconstitution with a diluent (i.e., saline to be
mixed with the vaccine to produce a liquid mixture). Presentations
can include vaccines alone or bundled or integrated with diluents
or delivery devices (e.g., droppers or syringes), which can
substantially increase the volume occupied in the supply chain.
When determining what vaccines to introduce and vaccine
presentations to procure, decision makers may consider the price
of the vaccine, disease burden, ease of administration, and existing
relationships with manufacturers. However, as previous history has
indicated, they may not fully anticipate the new vaccine’s potential
impact on the supply chain (e.g., the smallest vaccine may not be
the least expensive, the easiest to administer, or produced by a
manufacturer who already supplies other vaccines to the country).
For example, in 2006–2007 introducing the Rotateq and Rotarix
RVs to Latin and South American countries (Brazil, Ecuador, El
Salvador, Mexico, Nicaragua, Panama and Venezuela) displaced
other existing World Health Organization (WHO) recommended
Expanded Programs on Immunization (EPI) vaccines from already
limited refrigeratorand transportspace[1,2].Merck’s RotaTeq and
GlaxoSmithKline’s Rotarix were too large for many of the existing
supply chains, especially at the periphery, in Latin America. Many
clinics did not have sufficient refrigerator capacity to accommodate
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could not carry the extra thermoses and cold boxes needed to
transport the vaccines. Vaccine stock-outs occurred frequently,
limiting vaccine availability for patients. No training or operational
plans were in place to deal with these unanticipated consequences,
resulting in the expiration of large stocks of relatively expensive
vaccines [1]. Manufacturers were therefore compelled to reduce the
packaging size of these vaccines [1,3].
RV and PCV-7 are high priority vaccine candidates for
introduction into Thailand’s EPI. After neonatal complications
(45%), rotaviruses (16%) and pneumonia (11%) are the two
leading causes of under-five mortality in Thailand [4]. The
Vaccine Modeling Initiative (VMI), in collaboration with the
Southern Vaccine Research Team (SVRT) from the Prince of
Songkla University (PSU) in Hat Yai, Thailand, have developed
computational models of the Thailand supply chain to forecast the
impact of introducing these vaccines. Experiments explored
introducing different presentations of the RV and PCV-7 vaccines
separately and in various combinations.
Methods
We developed two models of the vaccine supply chain,
representing every storage location, refrigerator, freezer, transport
vehicle, and warehouse or clinic:
N Discrete event simulation model, i.e., Highly Extensible
Resource for Modeling Event-Driven Simulations (HERMES):
A detailed simulation model representing all the processes,
storage and administration locations, personnel and equipment
(transport, administration, and other), in the Southern Thai-
land supply chain developed in the program language Python,
using features provided by the SimPy package [5].
N Deterministic mathematical equation-based model (EBM): A
series of mathematical equations representing the flow of all
EPI vaccines from vaccine manufacturers to the Thailand
central depot and storage locations at all levels in Southern
Thailand to the patients. Development of the EBM occurred
in C++ and Microsoft Excel (Microsoft Corporation, Red-
mond, WA) and optimization in CPLEX (IBM Corporation,
Armonk, NY, USA), respectively [5].
Overview of Trang Province Vaccine Supply Chain
The Thailand vaccine supply chain consists of five levels:
national, regional, provincial, district, and sub-district. Our model
focuses on the province of Trang (one of seventy six provinces in
Thailand) supply chain (Figure 1) [6], which contains 152
locations: 1 regional site (cold storage capacity=34,660 L), 1
provincial site (660 L of refrigerator space and 1,080 L of freezer
space), 21 district sites (3 Municipal Health Centers=160 L of
refrigerator space and 23 L of freezer space, 8 District Health
Offices=24 L of refrigerator space, 16 L of freezer space and 9
Hospitals=245 L of refrigerator and freezer space each) and one
intermediary site, and 129 sub-district sites (160 L of refrigerator
space and 23 L of freezer space). Storage capacities and transport
capacities came from a sample of selected supply chain locations
and are consistent across a level. Data to construct the models
came from extensive inventories of and visits to locations at each
level as well as the Expanded Program on Immunization (EPI)
in association with the Ministry of Public Health (Bangkok,
Thailand).
Thailand procures their EPI vaccines from both domestic and
international manufacturers. The Government Pharmaceutical
Organization (GPO) repackages some vaccines into systematically-
sized batches for national distribution and delivers them to
regional sites which in turn send the vaccines down the supply
chain. The Trang province site receives vaccines monthly and
supplies district sites which include hospitals, municipal health
centers, and district health offices, and sub-district sites with
vaccines on a monthly basis. Each sub-district receives vaccines for
their own immunization sessions and for school-based vaccination
sessions. Designated vehicles from district and sub-district sites go
up to the next level to collect vaccines and bring them back as
scheduled. At the district level, immunization sessions occur only
once per week, and at the sub-district level, only once per month.
This is done to minimize open vial wastage, simplify immunization
surveillance, and manage personnel time devoted to the NIP. At
hospitals, birth doses are administered as births occur.
Supply Chain Processes and Policies
Both HERMES and the EBM represent every location (points of
distribution and administration) in the Trang province supply chain,
including their respective transport and storage capacities. The
number of vaccines currently stored in a refrigerator or freezer is
tracked as the vaccine inventory. This inventory is equal to the number
of vaccines remaining from the previous day minus the vaccines that
are shipped, administered (if the location is a district or sub-district), or
wasted, plus the number of vaccines that are delivered that day:
Vaccine Inventory on Dayt (number of doses)~
½Vaccine Inventory on Dayt 1 (doses)  z
½Vaccines Delivered on Dayt (doses) {
½Vaccines Removed on Dayt (doses) {
½Vaccinesadministered on Dayt (doses) 
Freezer (215uCt o225uC) and refrigerator (2uCt o8 uC) capacities
for each location were pre-defined. The percentage of physical
space within the freezer or refrigerator that can actually be used for
storage was the utilization rate. This was kept at a constant 85%
withinthemodeltoaccount forthe spaceused byothertemperature
sensitive products in addition to shelving. The total volume of
vaccines (the number of each type of vaccine multiplied by its
volume per vial) can never exceed the refrigerator or freezer’s
storage capacity multiplied by its utilization rate. The baseline
(current policy) shipping frequency occurs on a monthly schedule
wherein shipments from location to location occur at defined
frequencies that are specific to the level and transportation route.
While EPI policies in Thailand prescribe shipping vaccines monthly
below the regional level, some locations may distribute or collect
vaccines more or less frequently in a month as needed. The vaccine
shipments cannot contain more vaccine vials than the specified
storage capacity of that particular transport vehicle or person which
translates to a 464 vehicle at the provincial level, a cold box at the
district level, and a smaller vaccine carrier at the sub-district level.
Patient Demand and Arrival Rates
The model assumed that children would present to clinics for
immunization when they reach the appropriate age. District-
specific population age-distribution and birth rate data came from
the 2000 Population and Household Census district-specific data,
adjusted to 2010 values by a 1.45% annual population growth rate
[7]. The Thai National Health Statistic Office (NHSO) provided
monthly patient arrival data to adjust our projections. All arrival
rates were sub-divided into target age groups (newborns, 0–1 year,
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proportion of the total population represented by each sub-group
from the 2000 census and the number of visits each age group
needs to make for their respective vaccination schedule. Newborns
presented only to hospitals (i.e., district level locations). Based on a
previous study in Thailand, 90% of children sought vaccination in
public clinics (versus private locations) [8]. The amount of diluent
that is stored in the refrigerator the day prior to administration is
dependent on the rate of patient arrival.
Vaccine Wastage
The models account for three kinds of vaccine loss throughout
the vaccine supply chain: shipping, inventory, and open vial loss.
Shipping and inventory loss results from breakage or temperature
exposure. Open vial loss accounts for the incomplete consumption
offullvials(e.g.,only3dosesused froma 5-dosevial)asdescribed by
previous studies and the WHO’s Multi- Dose Vial Policy [2,9].
Closed vial wastage rates for each vaccine are input into the model
and account for breakage during transport and storage. It is difficult
to estimate closed vial wastage (i.e., wastage of vaccine before a vial
is opened) in shipping and storage because these rates are seldom
reported separately from open vial waste and may sometimes stem
from vaccine mismanagement [10]. Communications with vaccine
logistics experts suggested 1% inventory and shipping loss rates. We
then additionally explored 2% and 3% loss rates in sensitivity
analyses. Additionally, vaccine temperature profiles were input into
HERMES to track exposure to adverse temperatures. When a
vaccine is stored outside its preferred temperature range (e.g., when
there is not enough space in a cold storage device), it is stored at
room temperature, and expires at a faster rate.
Vaccine Characteristics
The supply chain in Trang Province contains seven current
vaccines whose total packaged volume per fully immunized child
(FIC) is 149.7 cm
3. Vaccine volumes include volumes of the
vaccine, the vaccine vials and the packaging material, which vary
by presentation and in some cases can be rather bulky [11].
Table 1 lists characteristics of current EPI vaccines as well as non-
EPI vaccines included in our introduction scenarios.
Sensitivity analyses
Table 2 lists model inputs used in our simulations. Sensitivity
analyses systematically explored the effects of ranging the following
parameter values: random inventory loss rate, i.e., percentage of
Figure 1. Trang Province Supply Chain Network.
doi:10.1371/journal.pone.0024673.g001
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i.e., percentage of vials damaged during shipping (range: 1–3%),
refrigerator capacity utilization, i.e., the percentage of refrigerator
space that can actually be used to store vaccines (range: 50–100%),
and shipping frequencies (twice per month, once per month and
once every two months). In addition, we varied the population
demand between a static (i.e., number of patients in a month is
fixed based on projected population estimates and does not
fluctuate from month to month) versus stochastic monthly
distribution [i.e., number of vaccine recipients in a given month
draws from a Poisson distribution with a mean of (l)], and the
birth rate in the target population to be vaccinated (range: 95–
105% of projected 2010 vaccine recipients).
Supply Chain Performance Measures
The overall objective of the EBM is to maximize the mean
vaccine supply ratio (i.e., a measure of vaccine availability for
patient arrivingto get immunized) acrossallimmunizationlocations
over the course of a year. The supply ratio is a measure of the
numberofarrivingpatientswhoreceivevaccinationbecausethereis
enough vaccine in stock and is computed in the EBM as follows:
Supply ratio~
(Number of arriving patients receiving vaccine)7
(Total number of arrivingpatients)
The constraints are the storage and transport capacities of each
location and the shipping frequencies as outlined above. The EBM
focused on maximizing supply ratio without considering costs.
The main purpose of the EBM was to compare and cross-
validate HERMES. Although the EBM may be used as an
optimization model, the goal of this study was to simulate new
vaccine introduction while accounting for the stochastic nature of
many of the parameters. Therefore, all of the results reported from
here on come from experiments performed with HERMES. We
also validated our HERMES model by comparing simulation
output with observations from the field in Thailand (e.g., prior to
new vaccine introduction, the same locations that demonstrated
capacity constraints in HERMES experienced capacity constraints
in real-life).
Results
Overall Impact
Introducing the new vaccines could clog up the refrigerator
space at the provincial and district levels and the transport cold
space at all levels thereby preventing other vaccines from reaching
the clinics and being available to patients who arrive to be
immunized. The new vaccine introduction decreases the supply
ratio (i.e., the percentage of people arriving at a clinic to be
immunized who subsequently have vaccines available to them).
Only the smallest vaccine (the 17.1 cm
3/dose RV) would have no
appreciable effect on vaccine availability at clinics. All other RV
and PCV-7 vaccines are too large for the current supply chain to
handle without modifications such as increasing storage or
transport capacity or shipping frequency.
Our findings were robust to varying shipping and inventory loss
rates (range: 1–3%), storage capacity utilization (85% and 100%),
and target population size (range: 95–105%). Switching from a
Table 1. Thailand NIP Vaccine Characteristics.
Vaccine
Status in National
Immunization
Program (NIP)*
Doses per
vial
Packaged
volume per
dose (cm3)
Administration
Schedule as per WHO
immunization profile
Temperature Profile
(preferred storage
medium) Sources
Bacille Calmette-Guerin
(BCG)
NIP vaccine 10 1.2 Birth 12 months at 2–8uC [34,35,36]
Hepatitis B (HepB) NIP vaccine 2 13.0 Birth 36 months at 2–8uC [34,35,36]
Diphtheria-tetanus-
pertussis (DTP)
NIP vaccine 10 3.0 1.5–2 years and 4–5 years 18 months at 2–8uC [34,35,36]
Diphtheria-tetanus-pertussis-
hepatitis B (DTP-HepB)
NIP vaccine 10 3.0 2,4 and 6 months 36 months at 2–8uC [34,35,36]
Oral polio vaccine (OPV) NIP vaccine 20 1.0 2,4,6,18 months and
4–5 years
12 months at 0 to 215uC,
1 month at 2–8uC
[34,35,36]
Measles (M) NIP vaccine 10 3.5 9 months 24 months at 2–8uC [34,35,36]
Japanese encephalitis (JE) NIP vaccine 2 12.6 1.5–2 years
(twice), and 2.5–3 years
24 months at 2–8uC [34,35,36]
Seven-valent pneumococcal
conjugate vaccine (PCV-7)
Non-NIP vaccine for
experimental introduction
1 55.9 2,4,6 and 15 months 24 months at 2–8uC [35,36,37]
Rotavirus (RV) Non-NIP vaccine for
experimental introduction
1 17.1 2 and 6 months 24 months at 2–8uC [35,36,38]
Rotavirus (RV) Non-NIP vaccine for
experimental introduction
1 45.9 2,4 and 6 months 24 months at 2–8uC [35,36,38]
Rotavirus (RV) Non-NIP vaccine for
experimental introduction
1 79.8 2,4 and 6 months 24 months at 2–8uC [35,36,38]
Rotavirus (RV) Non-NIP vaccine for
experimental introduction
1 156.0 2 and 6 months 24 months at 2–8uC [35,36,38]
Rotavirus (RV) Non-NIP vaccine for
experimental introduction
1 259.8 2 and 6 months 24 months at 2–8uC [35,36,38]
*School aged children and pregnant women were not considered in our analysis.
doi:10.1371/journal.pone.0024673.t001
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statistically significantly alter vaccine supply ratios across vaccine
introduction scenarios (i.e., their 95% confidence intervals
overlapped). However, reducing storage capacity utilization to
50%, and to reducing vaccine shipping frequency to every 30 days
and every 60 days did have significant effects on the supply ratios.
Therefore, from here on we report only results from scenarios that
employ 1% random inventory and shipping loss with a monthly
shipping policy and utilizing stochastic demand.
Impact on Storage Facilities
Introducing the new vaccines exceeds available refrigerator space
for the largest vaccine sizes, exceeds available refrigerator space for
all but the smallest two presentations alone (i.e., 17.1 and 45.9 cm
3/
dose) at the provincial level, and all but the smallest presentation at
the district level. All other presentations could overwhelm some
district level locations’ storage capacities. Figure 2 shows the
additional cold storage capacity needed at the provincial level and
Figure 3 shows the additional cold storage capacity required at the
district level following various RV and PCV-7 introduction
scenarios. The need for more storage is greater when shipping
frequency decreases, which could happen with the break down or
decommissioning of vehicles, loss of personnel, or political, weather,
or financial problems. For example, dropping the shipping
frequency to bi-monthly (once every two months) would require
an increase in storage capacity for all but the two smallest vaccines
at the provincial level and all presentations at the district level.
Impact on Transport Capacity
Transport cold capacity is a limitation as well. Current transport
cold capacity can only fully handle the two smaller (17.1 cm
3/dose
or the 45.9 cm
3/dose) RV presentations. No additional transport
capacity is required when delivering vaccines from the regional to
the provincial level; however, as figures 4 and 5 show, increases in
capacity are needed from the district and sub-district levels.
Decreasing shipping frequency exacerbates this need.
Impact on Vaccine Administration
The storage and transport bottlenecks inhibit the flow of all EPI
vaccines to many of the health clinics, thereby decreasing vaccine
availability for patients. Currently, the supply ratio for sub-districts
is 100%, i.e., everyone arriving at a clinic can get immunized.
Figure 6 shows how the supply ratios drop as the size of the new
vaccines increase. The impact on health clinics is widely variable.
Some sub-districts are able to maintain close to 100% supply
ratios. Others experience 10 to 15% drops, while others suffer
even more dramatic declines (down to 18% for the largest RV plus
PCV presentations).
Table 2. Model Parameters and Ranges for Sensitivity Analyses.
Variable Baseline value Range or Alternative
Demand
Annual population growth rate (%) 1.45 None
Number of newborns per year 10,910 10,365–11,456
0–1 year olds per year (excluding newborns) 26,778 25,439–28,117
2–3 year olds per year 26,778 25,439–28,118
3–4 year olds per year 26,778 25,439–28,119
Population distribution across months Stochastic Fixed
Supply Chain Network and Policies
Closed vial wastage per storage period (%) 2% 1–3%
Closed vial wastage per shipment (%) 2% 1–3%
Requisition, procurement and delivery schedules (interval between events in number of days) 30 15–60
Cold Chain Equipment
Cold truck capacity (liters) 6,480 None
Cold box capacity (liters) 19 None
Vaccine carrier (liters) 5 None
Regional level cold storage capacity (liters in refrigerator) 29,461 17,330–34,660
Provincial level cold storage capacity (liters in refrigerator) 560 330–659
District health office cold storage capacity (liters in refrigerator) 638 375–750
District municipal health center cold storage capacity (liters in refrigerator) 145 86–171
District hospital cold storage capacity (liters in refrigerator) 364 214–428
Sub-district cold storage capacity (liters in refrigerator) 119 70–140
Regional level cold storage capacity (liters in freezer) 231 136–272
Provincial level cold storage capacity (liters in freezer) 349 205–410
District health office cold storage capacity (liters in freezer) 11 7–13
District municipal health center cold storage capacity (liters in freezer) 65 39–77
District hospital cold storage capacity (liters in freezer) 167 99–197
Sub-district cold storage capacity (liters in freezer) 21 13–25
doi:10.1371/journal.pone.0024673.t002
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shipping frequency could not be maintained. Decreasing the
shipping frequencies to bi-monthly would result in supply ratios
ranging from close to 100% for smaller presentations, down to an
average of 5% for the largest vaccine size combination.
Vaccine availability across the year following vaccine introduc-
tion varied slightly showing natural stochasticity, but because we
evaluated routine immunization with RV and PCV rather than
campaign or roll-out strategies for immunization, the variations in
vaccine availability from one month to the next were not dramatic.
The variability of supply ratios and additional storage and
transport capacities that exists between districts and between sub-
districts is largely accounted for by the differences in population
demand at each site and at a given immunization session.
Discussion
Our results highlight the importance of evaluating the complex
system-wide effects of introducing a new vaccine into a vaccine
supply chain. Vaccine distribution is a complex process and any
change in the vaccines that flow through the supply chain may
have untoward ramifications. Supply chains may not be able to
accommodate the introduction of new vaccines and in turn delay
the delivery of new and current vaccines to arriving patients.
When developing a vaccine, vaccine scientists and manufacturers
should account for the impact of a vaccine’s presentation size.
Moreover, prior to a new vaccine introduction, public health
decision makers may want to review a country’s supply chain
structure and operations and evaluate possible adaptations;
otherwise, complications can be substantial.
Results from our model can be utilized in several ways. It can
help determine whether a supply chain is able to handle one or
multiple vaccine introductions. It can also help guide vaccine
presentation selection when different presentations are available.
Even when only one presentation is available, our model can help
identify where decision makers need to expand capacity (e.g.,
procure more trucks or refrigerators).
The use of computational models can be helpful in planning
new vaccine introduction and identify potential shortcomings well
in advance. Decision makers can make use of models to
understand complex repercussions that may not be outwardly
obvious. The use of computational models, while limited in public
health [12,13,14], have been used widely in many other industries
(e.g., manufacturing and distribution [15], transport [16],
aerospace [17], and military and defense [18]) as logistics planning
tools. Recent public health research using computational models
have helped evaluate various infection control measures
[19,20,21,22,23,24,25,26,27,28]. The Department of Health and
Human Services developed large scale computational models in
the response to the 2009 H1N1 pandemic [19,20,22,29,30]. There
are some examples in the literature of computational models of
perishable or temperature sensitive products such as food
processing and distribution [31]. Developing and implementing
computational models could save much time, expenses, and effort
in vaccine supply chain management, help inform decisions about
vaccine introductions, save costs and ensure adequate vaccination
of children. These advancements could lead to significant public
health benefits.
Limitations
By definition, models are simplifications of real life and cannot
account for every possible factor, relationship, or outcome [32,33].
Substantial data collection from a wide variety of different sources
was necessary in the construction of our model. Thailand is
currently in a transition to a new Vendor Managed Inventory
system. Some data used to construct the model comes from the
previous system. For example, the newer supply chain distributes
vaccines from the distributor to the hospitals directly which did not
occur in this model. Other data such as the availability and size of
transport vehicles may not be as reliable, since equipment
inventories are subject to change. Furthermore, random events
such as power outages were not captured for in our model. Our
experiments assumed that new vaccine introduction would occur
immediately and not gradually over a period of time. Rather than
visit every single location in the supply chain, our team sampled
sets of locations and extrapolated measurements to comparable
locations. We assumed that 60% of individuals seek immunization
at district locations and 40% at sub-district locations. Our model
assumed that shipments would occur as scheduled. Finally,
vaccination demand at each district and sub-district was estimated
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Figure 2. Extra Storage Capacity Required at the Provincial Store Following Each Vaccine Introduction Scenario (Results from
HERMES).
doi:10.1371/journal.pone.0024673.g002
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Figure 3. Extra Storage Capacity Required at the District Level Following Various Vaccine Introduction Scenarios (Results from
HERMES).
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Figure 4. Extra Transport Capacity Required at the District Level Following Various Vaccine Introduction Scenarios (Results from
HERMES).
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Figure 5. Extra Transport Capacity Required at the Sub-district Level Following Various Vaccine Introduction Scenarios (Results
from HERMES).
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performing sensitivity analyses indicated our results to be fairly
robust to changing parameter values. Actually, several of the
limitations (e.g., random disruptions to the supply chain) would
likely further reduce vaccine availability after RV or PCV-7
introduction.
Conclusion
Introducing the currently available formulations of PCV-7 and/
or RV vaccines to the routine EPI vaccine supply chain in
Thailand could substantially inhibit the delivery of all current EPI
vaccines. Therefore, considerable planning and modifications may
be necessary prior to the introduction of new vaccines. This study
emphasizes the importance of considering the effects on the entire
vaccine supply chain when introducing a new vaccine and how
computational models can assist public health officials, manufac-
turers, and other key decision makers plan for new vaccine
introduction.
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